The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) respiratory syncytial virus (RSV) vaccine, making it the first vaccine of its kind in the world. The vaccine, known as Synagis, is designed to protect older adults against RSV, a common respiratory virus that can lead to serious illness in older adults, infants, and young children.
RSV is a leading cause of respiratory illness in older adults, and the vaccine is expected to help reduce the burden of disease and the associated healthcare costs. The approval was based on the results of a clinical trial involving over 11,000 adults aged 60 years and older.
GSK says that the vaccine was found to be safe and effective in reducing RSV-associated lower respiratory tract infections (LRTIs) in older adults. The vaccine was shown to be 63% effective in preventing LRTIs caused by RSV in the first year after vaccination, and 70% effective in the second year.
The vaccine is administered via intramuscular injection and is typically given once per RSV season. The company says it is working with the US Centers for Disease Control and Prevention to develop guidelines for the use of the vaccine in the elderly population.
GSK plans to launch the vaccine in the US in the coming weeks. The company is also seeking regulatory approval for the vaccine in other countries, including Europe and Japan.
RSV is a common respiratory virus that causes mild to severe respiratory illness in people of all ages. It is particularly dangerous for infants, young children, and older adults, as well as individuals with weakened immune systems or chronic medical conditions.
0 Comments